Business
Approval and Issuance of U.S. Hu-PHEC Patent
Approval and Issuance of U.S. Hu-PHEC Patent.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 5426C Hemogenyx Pharmaceuticals PLC 11 February 2020 \n\nHemogenyx Pharmaceuticals plc\n(\"Hemogenyx\" or the \"Company\")\n \nApproval and Issuance of U.S. Hu-PHEC Patent\n \nHemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that a patent application entitled Post-Natal Hemogenic Endothelial Cells and their isolation and use has been approved by the United States Patent and Trademark Office. The patent will be issued on 25 February 2020 as Patent Number 10,570,373.\nPost-Natal Hemogenic Endothelial Cells (\"Hu-PHECs\") were posited and discovered by Hemogenyx's Co-Founder and CEO Dr Vladislav Sandler while working at Cornell University. The patent application was filed in 2014 and Hemogenyx was granted a world-wide exclusive sub-licensable licence for the patent by Cornell in 2015.\nIf fully and successfully developed, the Hu-PHEC technology would provide a new form of blood stem cell replacement therapy and potentially eliminate the principal problems that arise from the existing forms of treatment. \nHu-PHECs are a special sub-class of progenitor stem cell that generate hematopoietic stem cells (HSCs): bone marrow cells that give rise to all major types of blood cells. Hu-PHECs are thought to be cancer-free as they do not accumulate blood cancer-related mutations and/or chromosomal rearrangements. This makes them a perfect candidate for patient-specific, or autologous, bone marrow/HSC transplantations. This approach can potentially be used to treat blood cancers and auto-immune diseases with superior results. Importantly, it would remove the need to find a matching bone marrow donor, significantly expanding the number of patients who could be treated and it would also reduce the problem of transplant rejection which can occur under existing therapies.\nHu-PHEC-based technology presents several important advantages compared to other existing and developing technologies. Most of these advantages are due to the fact that Hu-PHECs are a naturally occurring cell type found in adult and postnatal mammalian tissues. They can be isolated and do not require heavy manipulation before use. In addition, Hu-PHECs can be propagated in vitro, allowing the introduction of therapeutic genes and gene modifications, and making them a prime candidate for curative gene therapy applications.\nDr Vla...